Monotherapy with fluoroquinolone or trimethoprim-Sulfamethoxazole for treatment of stenotrophomonas maltophilia infections

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 176-182

  Wang, Yu Lin ^a   Scipione, Marco R ^a   Dubrovskaya, Yanina ^a   Papadopoulos, John ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; LEVOFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ABDOMINAL INFECTION; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; CATHETER INFECTION; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; LUNG DISEASE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MICROBIOLOGICAL EXAMINATION; MIDDLE AGED; MONOTHERAPY; MORTALITY; PHYSICAL DISEASE BY BODY FUNCTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STENOTROPHOMONAS MALTOPHILIA; STENOTROPHOMONAS MALTOPHILIA INFECTION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VERY ELDERLY; BACTERIUM ISOLATION; COMPARATIVE EFFECTIVENESS; HOSPITAL MORTALITY; NONHUMAN; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STENOTROPHOMONAS MALTOPHILIA; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84891499399     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01324-13     Document Type: Article

References (23)

1. Cervia JS, Ortolano GA, Canonica FP. 2008. Hospital tap water as a source of Stenotrophomonas maltophilia infection. Clin. Infect. Dis. 46: 1485-1487. http://dx.doi.org/10.1086/587180
2. Safdar A, Rolston KV. 2007. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin. Infect. Dis. 45:1602-1609. http://dx.doi.org/10.1086/522998
3. Metan G, Hayran M, Hascelik G, Uzun O. 2006. Which patient is a candidate for empirical therapy against Stenotrophomonas maltophilia bacteraemia? An analysis of associated risk factors in a tertiary care hospital. Scand. J. Infect. Dis. 38:527-531. http://dx.doi.org/10.1080/00365540500452481
4. Looney WJ, Narita M, Muhlemann K. 2009. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect. Dis. 9:312-323. http://dx.doi.org/10.1016/S1473-3099(09)70083-0
5. Nicodemo AC, Paez JI. 2007. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur. J. Clin. Microbiol. Infect. Dis. 26:229- 237. http://dx.doi.org/10.1007/s10096-007-0279-3
6. Falagas ME, Valkimadi PE, Huang YT, Matthaiou DK, Hsueh PR. 2008. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J. Antimicrob. Chemother. 62: 889-894. http://dx.doi.org/10.1093/jac/dkn301
7. Czosnowski QA, Wood GC, Magnotti LJ, Croce MA, Swanson JM, Boucher BA, Fabian TC. 2011. Clinical and microbiologic outcomes in trauma patients treated for Stenotrophomonas maltophilia ventilatorassociated pneumonia. Pharmacotherapy 31:338-345. http://dx.doi.org/10.1592/phco.31.4.338
8. Samonis G, Karageorgopoulos DE, Maraki S, Levis P, Dimopoulou D, Spernovasilis NA, Kofteridis DP, Falagas ME. 2012. Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome. PLoS One 7:e37375. http://dx.doi.org/10. 1371/journal.pone.0037375
9. Wang WS, Liu CP, Lee CM, Huang FY. 2004. Stenotrophomonas maltophilia bacteremia in adults: four years' experience in a medical center in northern Taiwan. J. Microbiol. Immunol. Infect. 37:359-365.
10. Muder RR, Harris AP, Muller S, Edmond M, Chow JW, Papadakis K, Wagerner MW, Bodey GP, Steckelberg JM. 1996. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin. Infect. Dis. 22:508-512. http://dx.doi.org/10.1093/clinids/22.3.508
11. Tsiodras S, Pittet D, Carmeli Y, Eliopoulos G, Boucher H, Harbarth S. 2000. Clinical implications of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand. J. Infect. Dis. 32:651-656. http://dx.doi.org/10.1080/003655400459577
12. Metan G, Uzun O. 2005. Impact of initial antimicrobial therapy in patients with bloodstream infections caused by Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 49:3980-3981. http://dx.doi.org/10.1128/AAC.49.9. 3980-3981.2005
13. Kwa AL, Low JG, Lim TP, Leow PC, Kurup A, Tam VH. 2008.Independent predictors for mortality in patients with positive Stenotrophomonas maltophilia cultures. Ann. Acad. Med. Singapore. 37:826-830
14. Belvisi V, Fabietti P, Del Borgo C, Marocco R, Di Vincenzo E, Soscia F, Mastroianni CM. 2009. Successful treatment of Stenotrophomonasmaltophilia soft tissue infection with tigecycline: a case report. J. Chemother. 21:367-368
15. Weiss K, Restieri C, De Carolis E, Laverdiere M, Guay H. 2000. Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 45:363-365. http://dx.doi.org/10.1093/jac/45.3.363
16. Horan TC, Andrus M, Dudeck MA. 2008. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am. J. Infect. Control 36:309-332. http://dx.doi.org/10.1016/j.ajic.2008.03.002
17. Tseng CC, Fang WF, Huang KT, Chang PW, Tu ML, Shiang YP, Douglas IS, Lin MC. 2009. Risk factors for mortality in patients with nosocomial Stenotrophomonas maltophilia pneumonia. Infect. Control Hosp. Epidemiol. 30:1193-1202. http://dx.doi.org/10.1086/648455
18. Villarino ME, Stevens LE, Schable B, Mayers G, Miller JM, Burke JP, Jarvis WR. 1992. Risk factors for epidemic Xanthomonas maltophilia infection/colonization in intensive care unit patients. Infect. Control Hosp. Epidemiol. 13:201-206. http://dx.doi.org/10.1086/646510
19. Bonfiglio G, Cascone C, Azzarelli C, Cafiso V, Marchetti F, Stefani S. 2000. Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates. J. Antimicrob. Chemother. 45:115-117. http://dx.doi.org/10.1093/jac/45.1.115
20. Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K. 1994. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob. Agents Chemother. 38:624-627. http://dx.doi.org/10.1128/AAC.38.3.624
21. Munoz JL, Garcia MI, Munoz S, Leal S, Fajardo M, Garcia-Rodriguez JA. 1996. Activity of trimethoprim/sulfamethoxazole plus polymyxin B against multiresistant Stenotrophomonas maltophilia. Eur. J. Clin. Microbiol. Infect. Dis. 15:879-882. http://dx.doi.org/10.1007/BF01691222
22. San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L. 2004. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 48:168-171. http://dx.doi.org/10.1128/AAC.48.1.168-171.2004
23. Toleman MA, Bennett PM, Bennett DM, Jones RN, Walsh TR. 2007. Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg. Infect. Dis. 13:559 -565. http://dx.doi.org/10.3201/eid1304 .061378